Trading Advice for Enanta Pharmaceuticals Inc. ENTA including day trading swing trading and long term investing plans for ...

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the firm, Ratings reports.

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) on January 15. The company’s ...

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in a research note issued to investors on Tuesday,Benzinga reports.

Enanta Pharmaceuticals is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Neurocrine Biosciences (NBIX), finished the last trading session 0.3% higher at $135.42.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immuno ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that ...

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

Enanta Pharmaceuticals (ENTA) shares rallied 7.2% in the last trading session to close at $6.28. This move can be attributable to notable volume with a higher number of shares being traded than in ...